Abstract
Background and objective Neuroblastoma (NBL) is the most common extracranial solid cancer of childhood and is characterized by a remarkable biological heterogeneity, resulting in favorable or unfavorable outcomes. There are many prognostic factors like age, stage, histopathology, plasma and urinary markers and the molecular characteristics of tumor cells. Amplification of the MYCN gene, observed in 20-25% of NBL, is established as the most powerful prognostic factor, and so as the first tumor genetic marker which has been used for risk stratification in all neuroblastoma clinical trials. This article aims to investigate, in a series of 41 NBL patients ascertained in 2014, the relationship between amplification of MYCN and some other prognostic factors: patient’s age, histopathology, VMA/HVA ratio and LDH level.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
